I thought readers might be interested in how significant a "log reduction" number is in terms of efficacy in killing bacteria.
I asked Bing Copilot.... "what is the meaning of a log reduction in health research studies" and the answer came back.
Log Reduction Explained:A log reduction quantifies the reduction in microbial load using a logarithmic scale. Each “log” represents a tenfold reduction in the number of microorganisms.For instance:
A 1-log reduction means the number of germs is 10 times smaller.
A 2-log reduction means the number of germs is 100 times smaller.
A 3-log reduction corresponds to a 1000-fold reduction in microbial load, and so on.
Relationship Between Log Reduction and Percent Reduction:Microbiologists often express log reductions using scientific notation. To make these numbers more manageable, they use logarithmic scales.Here’s a pattern that helps relate log reductions to percent reductions:
1 log reduction = 90% reduction
2 log reduction = 99% reduction
3 log reduction = 99.9% reduction
4 log reduction = 99.99% reduction
5 log reduction = 99.999% reduction
6 log reduction = 99.9999% reduction
In the context of the RCE announcement it seems like these were very good results..
Key Findings from the study include:
• 1-hour Post-treatment Efficacy: Within the first hour post-treatment of invasive
(intracellular) Multidrug-Resistant A. baumannii in primary human epidermal keratinocytes,
R327 achieved a >6.5 log reduction, rendering the bacteria below the limit of quantification
(BLOQ). This demonstrates the rapid and effective bactericidal action of R327. In contrast,
ciprofloxacin did not show any reduction in intracellular bacterial burden at this early
timepoint.
• 24-hour Sustained Efficacy: R327 maintained its efficacy at >6.5 log or >99.9999%
reduction in intracellular bacteria even after 24 hours, a critical factor in infection
management. In comparison, ciprofloxacin treatment only resulted in ~1 log reduction in
bacterial numbers over the same period.
The WHO has listed A. baumannii as one of the top priority pathogens due to its high levels of
resistance to multiple antibiotics. A. baumannii is now a significant global health threat, known for
causing severe infections, both in hospital settings and within the community
- Forums
- ASX - By Stock
- RCE
- Ann: R327 Efficacy against WHO Priority Pathogen Acinetobacter B
Ann: R327 Efficacy against WHO Priority Pathogen Acinetobacter B, page-4
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RCE (ASX) to my watchlist
(20min delay)
|
|||||
Last
52.0¢ |
Change
0.005(0.97%) |
Mkt cap ! $120.5M |
Open | High | Low | Value | Volume |
54.0¢ | 54.0¢ | 52.0¢ | $4.485K | 8.497K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 17 | 52.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
53.0¢ | 14897 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 20282 | 0.515 |
1 | 290 | 0.510 |
1 | 50000 | 0.505 |
5 | 51000 | 0.500 |
1 | 6062 | 0.495 |
Price($) | Vol. | No. |
---|---|---|
0.530 | 14897 | 2 |
0.540 | 50460 | 5 |
0.545 | 12278 | 2 |
0.550 | 135601 | 3 |
0.560 | 5000 | 1 |
Last trade - 15.47pm 04/10/2024 (20 minute delay) ? |
Featured News
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
RCE (ASX) Chart |